Axial Spondyloarthritis Market
Axial Spondyloarthritis Market- Global Industry Size, Share, Trend Analysis and Forecast Report, 2018-2028, Segmented By Commercialized Therapies (Anti-Tumour Necrosis Factor Therapy(TNF),Anti-Interleukin Therapy(IL), Anti-Janus Kinase Therapy(JAK)); By Potential Pipeline Products (Anti-Janus Kinase Therapy(JAK), Anti-Interleukin (IL)-17 Therapy, Other) ;By Indication(Ankylosing Spondylitis, Non-Radiographic Axial Spondylitis); By Region (North America, Europe, The Asia Pacific, Latin America, The Middle East, and Africa)
- Published Date: August 2022
- Report ID: BWC22255
- Available Format: PDF
- Page: 240
Report Overview
The growth in the global axial spondyloarthritis market can be ascribed to the introduction of innovative products and the rising awareness about the disease. Moreover, the surge in the investments in drug research and development is further expected to propel the market growth over the forecast period 2022-2028.
Global Axial Spondyloarthritis Market - Market Trends & Forecast Report 2028
The global axial spondyloarthritis market was worth USD 1,910.7 Million in 2021, and it is further projected to reach USD 4,953.6 Million by 2028, at a CAGR of 14.8% during 2022-2028 (forecast period). The growth in the global axial spondyloarthritis market can be ascribed to introducing innovative products and the rising awareness of the disease. Moreover, the surge in drug research and development investments is further expected to propel market growth over the forecast period 2022-2028.
Axial Spondyloarthritis Market Overview
Axial spondyloarthritis in healthcare is a rheumatic disease affecting the axial skeleton. Irritable bowel illness, psoriatic arthritis, and reactive arthritis are among conditions that are typically associated with AxSpA. Axial spondyloarthritis is divided into two stages: radiographic axial spondyloarthritis (patients with structural damage in the sacroiliac joints or spine visible on radiographs) and non-radiographic axial spondyloarthritis (patients with no structural damage in the sacroiliac joints or spine visible on radiographs) (patients without such structural damage). Ankylosing spondylitis is also known as radiographic axial spondyloarthritis. Chronic inflammatory back pain, combined with the stiffness of the pelvis and lower back, is the most common symptom of axial spondyloarthritis; however, any portion of the spine can be affected. The cause of axial spondyloarthritis is unknown. Because the disease is inherited, genetics plays a significant impact.
Growth Driver
The Launch of Innovative Products Likely to Propel the Global Axial Spondyloarthritis Market
Biopharmaceutical businesses are attempting to align themselves with emerging market technologies in order to improve the complete system, from medication research to commercialization. To increase therapeutics and improve patient outcomes, firms in the global axial spondyloarthritis market are focusing increasingly on biologics and individualized therapy. Various market players are actively engaged in advancing and launching cutting-edge, innovative products, which is playing an important role in expanding the global axial spondyloarthritis market over the forecast period. For instance- For instance in August 2019, Eli Lilly and Company attained U.S. FDA approval for their product, Taltz injection 80 mg/mL, to be used in the treatment of active ankylosing spondylitis. Before this approval, the product was accepted for active psoriatic arthritis as well as moderate to severe plaque psoriasis in March 2016 and December 2017 correspondingly. Furthermore, Gilead Sciences, Inc. and Galapagos NV co-developed a product in September 2018 known as Filgotinib, which completed a phase 2 clinical trial for the indication of discreetly to severely active ankylosing spondylitis.
Similarly, In January 2022, four promising European health start-ups secured their place on Beyond Rheum, an 11-month open innovation program where they would be working on solutions to help patients with axial spondyloarthritis (axSpA). After the presentations to the jury panel, Midaia and ABATON from Germany, Tucuvi from Spain, and Promptly from Portugal were invited to take part in the program. Beyond Rheum is led by EIT Health Spain and supported by Novartis and aims to identify, validate, and pilot feasible, innovative solutions for the real needs of patients suffering from axial spondyloarthritis (axSpA) during their care process.
Restraints
High Costs of Drugs and Biologics
The cost of drugs and biologics used for the treatment of axial spondyloarthritis is on the higher side. The high cost associated with biologics is a result of the lengthy testing and manufacturing processes that is compulsory for the manufacturing the biologics. Moreover, high investments are required for the research and development activities. These factors, coupled with rigorous regulatory and approval provisions, are expected to restrain the growth of the axial spondyloarthritis (axSpA) market growth over the forecast period 2022-2028.
Impact of COVID-19 on the Global Axial Spondyloarthritis Market
The COVID-19 pandemic affected spondyloarthritis research and clinical development brutally. Companies working in axial spondyloarthritis were forced to shift their focus to pharmacological research and development for COVID-19 treatment to assist governments and communities throughout the world in establishing a new normal. Consequently, the rollout of developing medicines was postponed. Pharmaceutical companies had to dote their resources to developing and repurposing existing medication compounds to prevent and cure COVID-19. The majority of pharmaceutical companies embraced this technique in order to maximize revenue from COVID-19 medicine sales. These factors further influenced the development and launch of new medicines for axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis.
Due to the emergence of COVID-19, the manufacture and supply of axial spondyloarthritis medicines have been severely interrupted. Governments around the world enacted lockdowns which greatly impeded economic operations. This situation persisted until the second quarter (Q2) of 2020, significantly impacting the worldwide axial spondyloarthritis market and causing a decrease in therapeutic commercialization revenue. As a result of these incidents, patients with axial spondyloarthritis experienced restricted access to novel medicines. Nevertheless, several market players reported an increase in their revenues with the gradual recovery of the global economy.
Global Axial Spondyloarthritis Market – By Commercialized Therapies
Based on commercialized therapies, the global axial spondyloarthritis market has been segmented into anti-tumor necrosis factor therapy (TNF), anti-interleukin therapy (IL), and anti-janus kinase therapy (JAK). Amidst the segmentation, the anti-tumor necrosis factor therapy segment dominated the global axial spondyloarthritis market in the commercialized therapeutics category in 2021. Years of incremental and major advances in anti-tumor necrosis factor therapy have exhibited remarkable prospects for the treatment of a variety of axial spondyloarthritis symptoms. The Anti-TNF drugs are likely to remain the standard of care for patients who have a high level of disease activity on a regular basis.
Global Axial Spondyloarthritis Market- Regional Insights
In terms of the regional analysis, the global axial spondyloarthritis market can be segmented into Middle East & Africa, Latin America, Asia Pacific, Europe, and North America. Amidst the segmentation, North America is expected to account for the largest share in the axial spondyloarthritis (axSpA) market due to the higher percentage of total revenue spent on healthcare compared with other regions awareness and promising reimbursement. According to the Centers for Medicare and Medicaid Services, The United States health care spending rose 9.7%in 2020 and touched $4.1 trillion or $12,530 per person. The United States health spending accounted for 19.7% as a share of the nation's gross domestic product. Moreover, the Asia-pacific region is expected to experience the fastest growth in the Axial Spondyloarthritis (axSpA) Market over the forecast period 2022-2028.
Competitive Landscape
The global axial spondyloarthritis market is characterized by many local, regional, and global vendors. The key players operating in the global axial spondyloarthritis market are AbbVie Inc, Amgen Inc, Bristol- Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson Services Inc, Kyowa Kirin Co, Merck & Co, Novartis International AG, Pfizer Inc, Takeda Pharmaceutical Company, USB S.A, FunPep Co Ltd and other prominent players. The players maintain their dominance in the market by investing in research and development activities, integrating the latest and advanced technologies into their products, and launching improved products for the customers.
Recent Developments
- January 2022: UCB, a worldwide biopharmaceutical company, announced positive top-line interim analysis results exhibiting that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints. BE MOBILE 1 is the foremost study to assess the effectiveness and safety of bimekizumab in adults having active non-radiographic axial spondyloarthritis (nr-axSpA).
- January 2022: AbbVie announced that it submitted applications for approvals for upadacitinib (RINVOQ, 15 mg once daily) to the U.S. FDA and the European Medicines Agency (EMA) for the treatment of adults having active non-radiographic axial spondyloarthritis (nr-axSpA) with signs of inflammation who have responded incompetently to nonsteroidal anti-inflammatory drugs (NSAIDs). The applications are aided by the Phase 3 SELECT-AXIS 2 (Study 2) clinical trial.
Scope of Report
Attribute | Details |
Years Considered | Historical data – 2018-2021 |
Base Year – 2021 | |
Forecast – 2022 – 2028 | |
Facts Covered | Revenue in USD Million |
Market Coverage | United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Mexico, Saudi Arabia, United Arab Emirates, South Africa |
Product/Service Segmentation | By commercialized therapies, by potential pipeline products, by indication and by region |
Key Players | The key players operating in the global axial spondyloarthritis market are AbbVie Inc, Amgen Inc, Bristol- Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson Services Inc, Kyowa Kirin Co, Merck & Co, Novartis International AG, Pfizer Inc, Takeda Pharmaceutical Company, USB S.A, FunPep Co Ltd and other prominent players. |
By Commercialized Therapies
- Anti-tumour Necrosis Factor Therapy (TNF)
- Anti-Interleukin Therapy (IL)
- Anti-Janus Kinase Therapy (JAK)
By Potential Pipeline Products
- Anti-Janus Kinase Therapy (JAK)
- Anti-Interleukin (IL)-17 Therapy
- Other
By Indication
- Ankylosing Spondylitis
- Non-Radiographic Axial Spondylitis
By Region
-
- North America
- Europe
- The Asia Pacific
- Latin America
- The Middle East and Africa
- Research Framework
- Research Objective
- Product Overview
- Market Segmentation
- Research Methodology
- Qualitative Research
- Primary & Secondary Research
- Quantitative Research
- Market Breakdown & Data Triangulation
- Secondary Research
- Primary Research
- Breakdown of Primary Research Respondents, By Region
- Assumption & Limitation
- Qualitative Research
- Executive Summary
- Global Axial Spondyloarthritis Market Insights
- Industry Value Chain Analysis
- DROC Analysis
- Growth Drivers
- Restraints
- Opportunities
- Challenges
- Technological Advancement/Recent Development
- Regulatory Framework
- Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of New Entrants
- Threat of Substitutes
- Intensity of Rivalry
- Global Axial Spondyloarthritis Market Overview
- Market Size & Forecast by Value, 2018-2028
- By Value (USD Million)
- Market Share & Forecast
- By Commercialized Therapies
- Anti-tumor Necrosis Factor Therapy (TNF)
- Anti-Interleukin Therapy (IL)
- Anti-Janus Kinase Therapy (JAK)
- By Potential Pipeline Products
- Anti-Janus Kinase Therapy (JAK)
- Anti-Interleukin (IL)-17 Therapy
- Other
- By Indication
- Ankylosing Spondylitis
- Non-Radiographic Axial Spondylitis
- By Region
- North America
- Europe
- The Asia Pacific
- Latin America
- The Middle East and Africa
- By Commercialized Therapies
- Market Size & Forecast by Value, 2018-2028
- North America Axial Spondyloarthritis Market
- Market Size & Forecast by Value, 2018-2028
- By Value (USD Million)
- Market Share & Forecast
- By Commercialized Therapies
- By Potential Pipeline Products
- By Indication
- By Country
- United States
- Canada
- Market Size & Forecast by Value, 2018-2028
- Europe Axial Spondyloarthritis Market
- Market Size & Forecast by Value, 2018-2028
- By Value (USD Million)
- Market Share & Forecast
- By Commercialized Therapies
- By Potential Pipeline Products
- By Indication
- By Country
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Market Size & Forecast by Value, 2018-2028
- The Asia Pacific Axial Spondyloarthritis Market
- Market Size & Forecast by Value, 2018-2028
- By Value (USD Million)
- Market Share & Forecast
- By Commercialized Therapies
- By Potential Pipeline Products
- By Indication
- By Country
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Market Size & Forecast by Value, 2018-2028
- Latin America Axial Spondyloarthritis Market
- Market Size & Forecast by Value, 2018-2028
- By Value (USD Million)
- Market Share & Forecast
- By Commercialized Therapies
- By Potential Pipeline Products
- By Indication
- By Country
- Brazil
- Mexico
- Rest of Latin America
- Market Size & Forecast by Value, 2018-2028
- The Middle East & Africa Axial Spondyloarthritis Market
- Market Size & Forecast by Value, 2018-2028
- By Value (USD Million)
- Market Share & Forecast
- By Commercialized Therapies
- By Potential Pipeline Products
- By Indication
- By Country
- Brazil
- Mexico
- Rest of Latin America
- Market Size & Forecast by Value, 2018-2028
- Competitive Landscape
- List of Key Players and Their Offerings
- Market Share Analysis, 2021
- Competitive Benchmarking, By Operating Parameters
- Key Strategic Development (Merger, Acquisition, Partnership.)
- Impact of Covid-19 on Global Biomass Briquettes Industry
- Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) **
- AbbVie Inc.
- Amgen Inc.
- Bristol-Myers Sqiubb Company
- Eli Lilly and Company
- Johnson & Johnson Services Inc.
- Kyowa kirin Co
- Merck & co
- Novartis International AG
- Pfizer Inc
- Takeda Pharmaceutical Company
- USB S.A
- FunPep Co., Ltd
- Key Strategic Recommendations
*Financial information in case of non-listed companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable
List Of Figures
Figure 1: Global Axial Spondyloarthritis Market Segmentation
Figure 2: Global Axial Spondyloarthritis Industry Value Chain Analysis
Figure 3: Global Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 4: Global Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 5: Global Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 6: Global Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 7: Global Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 8: North America Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 9: North America Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 10: North America Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 11: North America Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 12: North America Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 13: Europe Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 14: Europe Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 15: Europe Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 16: Europe Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 17: Europe Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 18: The Asia-Pacific Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 19: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 20: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 21: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 22: The Asia-Pacific Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 23: Latin America Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 24: Latin America Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 25: Latin America Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 26: Latin America Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 27: Latin America Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 28: The Middle East & Africa Axial Spondyloarthritis Market Size, By Value (USD Million), 2018-2028
Figure 29: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Commercialized Therapies, By Value, 2018-2028
Figure 30: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Potential Pipeline Products, By Value, 2018-2028
Figure 31: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Indication, By Value, 2018-2028
Figure 32: The Middle East & Africa Axial Spondyloarthritis Market Share (%), By Country, By Value, 2018-2028
Figure 33: Global Axial Spondyloarthritis Market Share Analysis, 2021
List Of Tables
Table 1: Global Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 2: Global Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 3: Global Axial Spondyloarthritis Market Size, By Indication, By Value (USD Million), 2018-2028
Table 4: Global Axial Spondyloarthritis Market Size. By Country, By Value (USD Million), 2018-2028
Table 5: North America Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 6: North America Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 7: 28 North America Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028
Table 8: 28 North America Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028
Table 9: Europe Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 10: Europe Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 11: 40 Europe Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028
Table 12: 40 Europe Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028
Table 13: The Asia-Pacific Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 14: The Asia-Pacific Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 15: The Asia-Pacific Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028
Table 16: The Asia-Pacific Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028
Table 17: Latin America Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 18: Latin America Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 19: Latin America Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028
Table 20: Latin America Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028
Table 21: The Middle East & Africa Axial Spondyloarthritis Market Size, By Commercialized Therapies, By Value (USD Million), 2018-2028
Table 22: The Middle East & Africa Axial Spondyloarthritis Market Size, By Potential Pipeline Products, By Value (USD Million), 2018-2028
Table 23: The Middle East & Africa Axial Spondyloarthritis Market Size (USD Million), By Indication, By Value 2018-2028
Table 24: The Middle East & Africa Axial Spondyloarthritis Market Size (USD Million), By Country, By Value 2018-2028
Table 25: List of Key Players and Their Offerings
Table 26: Competitive Benchmarking, by Operating Parameters
Table 27 AbbVie Inc. Company Overview
Table 28 AbbVie Inc. Financial Overview
Table 29 Amgen Inc. Company Overview
Table 30 Amgen Inc. Financial Overview
Table 31 Bristol-Myers Sqiubb Company Overview
Table 32 Bristol-Myers Sqiubb Company Financial Overview
Table 33 Eli Lilly and Company Overview
Table 34 Eli Lilly and Company Financial Overview
Table 35 Johnson & Johnson Services Inc. Company Overview
Table 36 Johnson & Johnson Services Inc. Financial Overview
Table 37 Kyowa kirin Co Company Overview
Table 38 Kyowa kirin Co Financial Overview
Table 39 Merck & co Company Overview
Table 40 Merck & co Financial Overview
Table 41 Novartis International AG Company Overview
Table 42 Novartis International AG Financial Overview
Table 43 Pfizer Inc. Company Overview
Table 44 Pfizer Inc. Financial Overview
Table 45 Takeda Pharmaceutical Company Overview
Table 46 Takeda Pharmaceutical Company Financial Overview
Table 47 USB S.A Company Overview
Table 48 USB S.A Financial Overview
Table 49 FunPep Co., Ltd Company Overview
Table 50 FunPep Co., Ltd Financial Overview
Market Segmentation
By Commercialized Therapies
- Anti-tumour Necrosis Factor Therapy (TNF)
- Anti-Interleukin Therapy (IL)
- Anti-Janus Kinase Therapy (JAK)
By Potential Pipeline Products
- Anti-Janus Kinase Therapy (JAK)
- Anti-Interleukin (IL)-17 Therapy
- Other
By Indication
- Ankylosing Spondylitis
- Non-Radiographic Axial Spondylitis
By Region
- North America
- Europe
- The Asia Pacific
- Latin America
- The Middle East and Africa
To request a free sample copy of this report, please complete the form below.
We value your investment and offer free customization with every report to fulfil your exact research needs.
Frequently Asked Questions (FAQs):
RELATED REPORTS
WHY CHOOSE US
-
24/7 Research Support
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
-
Custom Research Service
Ask the Analyst to customize an exclusive study to serve your research needs
-
Quality & Accuracy
Ask the Analyst to customize an exclusive study to serve your research needs
-
Data Visualization
As the business world is changing dynamically every day. We need to stay pin point in relation to data management and optimum data utilization
-
Information security
We never share your personal and confidential information. Your personal information is safe and secure with us.